It found the drug has even greater benefits for patients with severe AD than those in the earlier stages of the disease, the only group of patients that would normally be prescribed the treatment.
, of the University’s Division of Psychiatry, was among the experts who conducted the research, which was published recently in the New England Journal of Medicine. He said: “The National Institute for Health and Clinical Excellence (NICE) has advised use of this drug for people with mild to moderate dementia for some years but until now there has not been sufficient evidence to suggest its use is worthwhile in patients who are in the later stages of the illness.
“Our study has shown that the drug can have significant benefits to patients with severe dementia in slowing the decline in cognition and function. This large scale study has plugged a gap in our knowledge in a big way and this is important and helpful news for people with dementia and their carers.”
Clinically important benefits
Around 750,000 people in the UK and 18 million worldwide suffer from AD. The multi-centre study, conducted in collaboration with King’s College London and funded by the Medical Research Council (MRC) and the Alzheimer’s Society, looked at two drugs: donepezil and memantine. Donepezil is the most commonly prescribed of the dementia drugs but doctors are currently advised to stop prescribing the drug when the disease progresses to moderate and severe because there has been no clear evidence that continuing treatment is beneficial to patients.
The study found that those patients who continued to take donepezil showed considerably less decline in cognition, including memory, orientation and language skills, and function (retained ability to carry out simple daily tasks and self-care) than those taking a placebo drug.
The benefits were clinically important and were actually greater than in patients with less severe AD. While the effect was slightly smaller, starting memantine treatment also resulted in significantly better cognitive and functional abilities compared with those taking a placebo.
Professor Clive Ballard, Director of Research at Alzheimer’s Society, said: “Thanks to the Alzheimer’s drug donepezil, tens of thousands of people in the early to moderate stages of the condition are able to recognise their family for longer, play with their grandchildren and make vital plans for the future. This major new trial now shows that there could also be significant benefits on continuing the treatment into the later stages too. There are 750,000 people with dementia in the UK, yet currently prescription levels of Alzheimer’s drugs are still low. If this is to change we have to improve the shocking diagnosis rates and ensure everyone is given the opportunity to try treatments.”
The study was sponsored by King’s College London and funded by the UK Medical Research Council (MRC) and Alzheimer’s Society. Pfizer-Eisa and Lundbeck donated supplies of drugs but had no involvement in the study design, conduct analyses or reporting.
A full copy of the academic paper can be found on the website for the New England Journal of Medicine.
— Ends —
For up to the minute media alerts, follow us on Twitter
Notes to editors: The University of Nottingham, described by The Sunday Times University Guide 2011 as ‘the embodiment of the modern international university’, has 40,000 students at award-winning campuses in the United Kingdom, China and Malaysia. It is ranked in the UK’s Top 10 and the World’s Top 75 universities by the Shanghai Jiao Tong (SJTU) and the QS World University Rankings. It was named ‘the world’s greenest university’ in the UI GreenMetric World University Ranking 2011.
More than 90 per cent of research at The University of Nottingham is of international quality, according to the most recent Research Assessment Exercise. The University’s vision is to be recognised around the world for its signature contributions, especially in global food security, energy & sustainability, and health. The University won a Queen’s Anniversary Prize for Higher and Further Education in 2011, for its research into global food security.
More information is available from Dr Rob Jones on +44 (0)115 823 0429, firstname.lastname@example.org
Emma Thorne – Media Relations Manager
Email: email@example.com Phone: +44 (0)115 951 5793 Location: King’s Meadow Campus